Tenaya Therapeutics (NASDAQ:TNYA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed [Yahoo! Finance]
Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.
Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at Chardan Capital from $9.00 to $8.00. They now have a "buy" rating on the stock.
Tenaya Therapeutics Announces Pricing of Public Offering